Incyte Corporation (INCY)
| Market Cap | 13.97B |
| Revenue (ttm) | 3.77B |
| Net Income (ttm) | 745.44M |
| Shares Out | 224.86M |
| EPS (ttm) | 3.30 |
| PE Ratio | 18.82 |
| Forward PE | 13.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,445,216 |
| Open | 62.28 |
| Previous Close | 62.69 |
| Day's Range | 61.42 - 63.08 |
| 52-Week Range | 50.27 - 67.36 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 71.43 (+15.01%) |
| Earnings Date | Jul 30, 2024 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast ... [Read more]
Financial Performance
In 2023, Incyte's revenue was $3.70 billion, an increase of 8.87% compared to the previous year's $3.39 billion. Earnings were $597.60 million, an increase of 75.42%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for INCY stock is "Buy." The 12-month stock price forecast is $71.43, which is an increase of 15.01% from the latest price.
News
Incyte Announces Final Results of Tender Offer
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Final Results of Tender Offer.
Incyte Announces Preliminary Results of Tender Offer
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Preliminary Results of Tender Offer.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Malignant Mesothelioma Pipeline Landscape Analysis, 2024 - Incyte's INCB001158 and Polaris' Pegargiminase Lead the Way in Mechanism-Specific Interventions
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Malignant Mesothelioma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.
Incyte Completes Acquisition of Escient Pharmaceuticals
WILMINGTON, Del. & SAN DIEGO--(BUSINESS WIRE)---- $INCY--Incyte Completes Acquisition of Escient Pharmaceuticals.
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings.
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT) i...
How Does Incyte Stock's Decline During The 2022 Inflation Shock Compare With The 2008 Crash?
The stock price of Incyte Incyte , a biopharmaceutical company, trades at $58 per share, about 43% below its peak level of $100 seen in January 2021. INCY stock was trading at around $76 in early June...
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO24--Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress.
S&P 500 Gains and Losses Today: Incyte Stock Pops on Buyback Plan
Major U.S. equities indexes were mixed and little changed Monday to kick off a new trading week that will provide investors with a few key economic data points.
Incyte to buy back $1.67 billion of its own stock in Dutch auction tender
Biotech Incyte Corp. said Monday its board has approved a share buyback of up to $2 billion and the company has commenced a modified Dutch auction tender for up to $1.67 billion worth.
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock.
Incyte misses quarterly profit on weak sales of lead drug
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%.
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs.
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
WILMINGTON, Del. & SAN DIEGO--(BUSINESS WIRE)---- $INCY--Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists.
Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 202...
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
WILMINGTON, Del. and HONG KONG--(BUSINESS WIRE)---- $INCY--Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia.
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that ...
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis.
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa.
New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2024--New Data from Incyte's Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Lives through Generative AI
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced the launch of The Unseen Journey, a program that brings to life the hidden emotional and physical toll of myeloproliferative ne...
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitam...